Cacospongionolide B
Cacospongionolide B is an orally active sesterterpene compound that can be isolated from Fasciospongia cavernosa. Cacospongionolide B is a secreted phospholipase A2 (sPLA2) inhibitor with an IC50 of 4.3 μM. Cacospongionolide B exhibits antibacterial activity. Cacospongionolide B downregulates the expression of iNOS, COX-2 and TNF-α by inhibiting NF-κB nuclear translocation and its DNA binding, and simultaneously selectively and irreversibly inhibits sPLA2 enzymatic activity. Cacospongionolide B can be used in studies related to bacterial infection and adjuvant arthritis.
For research use only. We do not sell to patients.
- CAS No.: 172854-76-1
- Formula: C25H36O4
- Molecular Weight:400.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Phospholipase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
sPLA2 4.3 μM (IC50) |
iNOS |
COX-2 |
TNF-α |
In Vitro
Cacospongionolide B potently inhibits the growth of Bacillus subtilis and Micrococcus luteus, with an MIC of 0.78 μg/mL for both strains[1].
Cacospongionolide B (0.5-5 μM; 2-18 h) concentration-dependently reduces the release of TNF-α (IC50 = 260 nM), Nitrite (IC50 = 330 nM), and PGE2 (IC50 = 197 nM), inhibits the protein expression of iNOS and COX-2, significantly decreases TNF-α mRNA expression, suppresses NF-κB DNA-binding activity, blocks the nuclear translocation of the p65 subunit, and interferes with the phosphorylation of IκB-α at serine 32 in Zymosan (HY-159069)-stimulated mouse peritoneal macrophages; it also reduces the production of TNF-α and PGE2 in Zymosan-stimulated human monocytes[2].
Cacospongionolide B irreversibly and selectively inhibits sPLA2 in vitro, and exhibits the strongest inhibitory potency against human recombinant synovial sPLA2 (IC50 = 4.3 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mouse peritoneal macrophages
-
Concentration:0.5 μM, 1 μM, 5 μM
-
Incubation Time:30 min pre-incubation followed by 60 min to 18 h reaction
-
Result:Decreased Zymosan-induced iNOS and COX-2 protein expression.
Retained the p65 subunit in the cytoplasm, preventing its nuclear translocation, while reducing IκB-α phosphorylation at Ser32 and increasing IκB-α expression in the NF-κB pathway.
In Vivo
Cacospongionolide B (50-100 μg/ear; topical application to the ear; single administration; 4 h treatment) exerts anti-inflammatory and anti-edema effects and reduces myeloperoxidase levels in a TPA (HY-18739)-induced mouse ear edema model[3].
Cacospongionolide B (20 mg/kg; oral administration; once daily from day 13 to day 17; treatment continues until day 18) reduces paw edema volume and inhibits sPLA2 activity to alleviate chronic inflammation in a Mycobacterium-induced rat adjuvant arthritis model[3].
Cacospongionolide B (5-20 mg/kg; oral administration; single dose) exerts significant anti-acute inflammatory and edema-reducing effects in a Carrageenan (HY-125474)-induced mouse paw edema model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 (female, 25-30 g)[2]
-
Dosage:50 nmol/pouch (2-hour assessment; 12-hour assessment); 100 nmol/pouch (2-hour assessment; 12-hour assessment)
-
Administration:o.a.; single dose (2-hour assessment); initial dose followed by second dose 8 hours later (12-hour assessment)
-
Result:Reduced TNF-α levels in air pouch exudates at 2 hours post-zymosan administration, without significantly affecting leukocyte infiltration.
Reduced leukocyte infiltration, nitrite levels, and PGE2 levels in air pouch exudates at 12 hours post-zymosan administration.
Reduced iNOS and COX-2 protein expression in cells isolated from 12-hour zymosan-stimulated air pouch exudates.
-
Animal Model:Swiss mice (20-25 g, TPA-induced ear oedema model)[3]
-
Dosage:50 μg ear-1; 100 μg ear-1
-
Administration:topical; single dose; processed 4 h after TPA administration
-
Result:Achieved 43.4% oedema inhibition and 64.3% myeloperoxidase inhibition at 50 μg ear-1.
Achieved 54.6% oedema inhibition and 70.9% myeloperoxidase inhibition at 100 μg ear-1.
-
Animal Model:Swiss mice (female, 20-25 g, carrageenin-induced paw oedema model)[3]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:p.o.; single dose; observed up to 5 h post-induction
-
Result:Significantly reduced paw oedema at 1 and 3 hours at 5 mg/kg.
Significantly reduced paw oedema at 1, 3, and 5 hours at 10 mg/kg.
Significantly reduced paw oedema at 1, 3, and 5 hours at 20 mg/kg.
-
Animal Model:Lewis rats (female, 126-150 g, adjuvant-induced arthritis model)[3]
-
Dosage:20 mg/kg
-
Administration:p.o.; once daily; 5 days; total 18 days
-
Result:Significantly reduced mean paw oedema on days 15 and 18.
Significantly inhibited elevated sPLA2 activity in paw homogenates.
Did not modify eicosanoid levels in serum, stomach, or paw homogenates.
Caused no toxic effects in treated rats.
Chemical Information
-
CAS No. 172854-76-1
-
Molecular Weight 400.55
-
Formula C25H36O4
-
SMILES
O=C(O[C@H]1O)C=C1[C@H](OC2)CC=C2CC[C@@]3([C@]4([H])[C@@](CC[C@@H]3C)(C(CCC4)=C)C)C
-
Structure Classification
-
Initial Source
Fasciospongia cavernosa
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)